The Future 50

Yoon S. Byun—The Boston Globe/Getty Images


Vertex Pharmaceuticals


Vertex got its start ­making a hepatitis C drug, but it has more recently homed in on medicine that treats symptoms of cystic fibrosis, a genetic disease that afflicts 75,000 people worldwide. Its two bestselling drugs, Orkambi and Kalydeco, account for 87% of its $2.6 billion in revenue. And in February, Vertex received approval of a third CF drug, Symdeko, which earned $186 million in its first quarter on the market—more than twice what analysts expected. The success of the drugs has helped Vertex more than double its revenue in three years.

Looking for leads, investment insights, or competitive intelligence?

Overall Score



Health Care




Jeffrey M. Leiden



HQ Location


Revenues ($M) (Past 12 Months)


Profits ($M) (Past 12 Months)


Market Value as of Oct. 10, 2018 ($M)


Revenue and net income for 12 months ended June 30, 2018. Sources: Bloomberg; S&P Global.

News about Vertex Pharmaceuticals

The 5 Best Biotech and Health Care Stocks to Buy for 2019 Now That Congress Can’t Repeal Obamacare

With Congress split between Republicans and Democrats, pharma and biotech stocks are ready to surge.

Read More →
These Are the Health Care Companies Poised for Explosive Growth

From genetic testing giants to copycat drug manufacturers, here are the global companies set to make a mark on medicine.

Read More →
The Best Investing Advice for 2018 From Fortune’s Experts

Insights from our annual roundtable on the best stocks and the biggest risks.

Read More →
Nasdaq and S&P Reach New Highs Powered by Tech Stocks

IBM dragged, serving as a tech stock outlier. Energy and health sectors advanced.

Read More →